Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients

Growth Hormone and IGF Research

Volumn 18, Issue 4, 2008, Pages 318-324

  Fideleff, H L ^a   Boquete, H R ^a   Stalldecker, G ^b   Giaccio, A V ^a   Sobrado, P G V ^a  

^a Hospital General De Agudos Teodoro Alvarez   (Argentina)

^b Hospital Pirovano   (Argentina)

Author keywords

Bone mineral content; Growth hormone deficiency; Growth hormone replacement; Untreated growth hormone deficient patients, cardiovascular risk factors

Indexed keywords

GLUCOSE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOPHYSIS HORMONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; BONE DENSITY; BONE MASS; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; FEMALE; FEMUR NECK; FOLLOW UP; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HUMAN; LIPID METABOLISM; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; TWO DIMENSIONAL ECHOCARDIOGRAPHY; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AGED; BLOOD PRESSURE; BODY COMPOSITION; BONE DENSITY; CARDIOVASCULAR PHYSIOLOGY; FEMALE; GROWTH DISORDERS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; MALE; MIDDLE AGED;

EID: 44349107604     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2008.01.002     Document Type: Article

References (30)

1. Cuneo R.C., Salomon F., McGauley G.A., and Sönksen P.H. The growth hormone deficiency syndrome in adults. Clin. Endocrinol. (Oxf) 37 (1992) 387-397
2. Carroll P.V., Christ E.R., Bengtsson B.-A., et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 83 (1998) 382-395
3. Jorgensen J.O.L., Pedersen S.A., Thuesen L., et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1 (1989) 1221-1225
4. Salomon F., Cuneo R.C., Hesp H., and Sönksen P.H. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med. 321 (1989) 1797-1803
5. Bengtsson B.-A., Edén S., Lünn I., et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J. Clin. Endocrinol. Metab. 76 (1993) 309-317
6. Growth Hormone Research Society, Consensus guidelines for the diagnosis and treatments of adults with growth hormone deficiency: summary statement of the growth hormone research society workshop on adult growth hormone deficiency, J. Clin. Endocrinol. Metab. 83 (1998) 379-381.
7. Fideleff H.L., Boquete H., Giaccio A., and Sobrado P. Medium and long-term outcome of growth hormone therapy in growth hormone deficient adults. Medicina (B Aires) 66 (2006) 296-302
8. Chrisoulidou A., Beshyah S., Rutherford O., et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J. Clin. Endocrinol. Metab. 85 (2000) 3762-3769
9. Boquete H.R., Sobrado P.G., Fideleff H.L., et al. Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. J. Clin. Endocrinol. Metab. 88 (2003) 4702-4708
10. Gibney J., Wallace J.D., Spinks T., et al. The effect of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 84 (1999) 2596-2602
11. Molitch M., Clemmons D., Malozowski S., Merrian G., Shalet S., and Vance M. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 91 (2006) 1621-1634
12. Koltowska-Häggström M., Mattsson A.F., Monson J.P., et al. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life?. Eur. J. Endocrinol. 155 (2006) 109-119
13. Svensson J., Finer N., Bouloux P., et al. Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. Grow. Horm. IGF Res. 17 (2007) 67-76
14. Sesmilo G., Biller B.M., Llevadot J., et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann. Intern. Med. 133 (2000) 111-122
15. Maison P., Griffin S., Nicoue-Beglah M., Haddad N., Balkau B., and Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, Placebo-controlled trials. J. Clin. Endocrinol. Metab. 89 (2004) 2192-2199
16. Van der Klaauw A., Romijn J., Biermasz N., et al. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. Eur. J. Endocrinol. 155 (2006) 701-708
17. Jorgensen J.O., Vahl N., Hansen T.B., Thuesen L., Hagen C., and Christiansen J.S. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clin. Endocrinol. 45 (1996) 681-688
18. Span J., Pieters G., Sweep F., Hermus A., and Smals A. Gender differences in rhGH-induced changes in body composition in GH-deficient adults. J. Clin. Endocrinol. Metab. 86 (2001) 4161-4165
19. Woodhouse L.J., Mukherjee A., Shalet S.M., and Ezzat S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocrinol. Rev. 27 (2006) 287-317
20. Abs R., Feldt-Rasmussen U., Mattsson A.F., et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur. J. Endocrinol. 155 (2006) 79-90
21. Gotherstrom G., Svensson J., Koranyi J., et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J. Clin. Endocrinol. Metab. 86 (2001) 4657-4665
22. Wilhelm B., and Kann P.H. Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults. Med. Klin. (Munich) 99 (2004) 569-577
23. Boguszewski C., Meister L., Zaninelli D., and Radominski R. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur. J. Endocrinol. 152 (2005) 67-75
24. Bouillon R., Koledova E., Bezlepkina O., et al. Bone status and fracture prevalence in Russian adults with childhood-onset growth hormone deficiency. J. Clin. Endocrinol. Metab. 89 (2004) 4993-4998
25. Genant H., Gluer C., and Lotz J. Gender differences in bone density, skeletal geometry, and fracture biomechanics. Radiology 190 (1994) 636-640
26. Bass S., Delmas P., Pearce G., Hendrich E., Tabensky A., and Seeman E. The differing tempo of growth in bone size, mass, and density in girls in region-specific. J. Clin. Invest. 104 (1999) 795-804
27. Cutfield W., Wilton P., Bennmarker H., et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 355 (2000) 610-613
28. Yuen K.C., Frystyk J., White D.K., et al. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin. Endocrinol. (Oxf) 63 (2005) 428-436
29. Gerstein H.C. Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease. Evidence-Based Cardiovas. Med. 1 (1997) 87-88
30. Coutinho M., Gerstein H.C., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95.783 individuals followed for 12.4 years. Diabet. Care 22 (1999) 233-240